Koo - As a general rule of thumb I go on the basis of 1X's potential annual sales less an adjustment for outstanding royalty agreements. This would let the acquiring company recoupe all of their capital within 3 years and make profit for the remaining time of the patent life. What's really nice about ABL is that the patent is good to 2034. With that length of time on the patent it should push the valuation to the upper limits.

I have said in the past that IMO peak sales could set a new record for gross sales of any single drug on the planet. Humera had sales of just over $20 billion last year. Take it from there Koo. This is all just speculation at this point. Let's see if we first pass the trial and what valuations analysts and BP's come up with.

tada